NCT04492566已完成不适用
Supervised Safety and Feasibility Evaluation of the Zone-MPC Control Algorithm Integrated Into the iAPS in Pregnant Patients With Type 1 Diabetes With Extension Into Outpatient at Home
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 5
- 主要终点
- Time in Target Glucose Range
研究概览
简要总结
This clinical trial is a safety and feasibility study to assess the performance of an artificial pancreas (AP) system using the Zone Model Predictive control (Zone-MPC) and Health Monitoring System (HMS) algorithms embedded into the iAPS platform for pregnant patients with type 1 diabetes (T1D).
详细描述
The system will be evaluated on up to 21 pregnant adult subjects with type 1 diabetes age 18-45 years old at three clinical sites (Sansum Diabetes Research Institute, Mayo Clinic Rochester MN and Mt Sinai Hospital, New York City). Subjects will complete a 48-60 hour closed-loop (CL) session in a supervised outpatient environment with medical staff present. During the session, subjects will bolus for all meals and snacks, and will perform their usual daily activities while being accompanied by study medical staff.
For subjects who wish to continue use of the system, they will be offered the option of continuing use of the system at home in an extension phase, for the rest of their pregnancy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 and ≤ 45 years at the time of screening.
- •Clinical diagnosis of type 1 diabetes
- •Currently using an insulin pump at the time of screening.
- •HbA1c ≤ 9%, as performed by point of care or central laboratory testing.
- •Pregnant 14+0/7 to 32+6/7 weeks gestation.
- •Singleton pregnancy without any other significant known complications, such as preeclampsia, premature rupture of membranes, 2nd/3rd trimester bleeding, fetal growth or fluid abnormalities.
- •No proven or suspected fetal malformations diagnosed in the current pregnancy.
- •Bolus for all meals and snacks that contain ≥ 5 grams of carbohydrate.
- •Willing to switch to, or continue Novolog or Humalog for the closed-loop session.
- •Willingness not to start any new non-insulin glucose-lowering agent during the course of the trial.
- •Willing to abide by the study protocol and use study-provided devices.
- •Have a care partner with the following responsibilities: knowing subject whereabouts and being promptly available for contact by study staff during the day and night, residing in the same dwelling as subject during the night, being agreeable to all device training during the supervised HCL session and additional training on hyper- and hypoglycemia treatment, and assisting with emergency care if needed, such as transportation to the hospital or emergency department.
排除标准
- •Known unstable cardiac disease or untreated cardiac disease, as revealed by history or physical examination.
- •Concurrent use of Afrezza or any non-insulin glucose-lowering agent other than metformin (including GLP-1 agonists, Pramlintide, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas).
- •Hemophilia or any other bleeding disorder
- •Prior history of Preterm Premature Rupture of Membranes (PPROM)
- •Significant hyperemesis interfering with carbohydrate intake
- •Laboratory results:
- •Abnormal liver or renal function (Transaminase >2 times the upper limit of normal, creatinine > 1.5 mg/dL)
- •Liver and renal function testing drawn at screening visit or within three months prior to screening (for other purposes) will suffice for enrollment purposes
- •Dermatological conditions that would preclude wearing a CGM sensor or infusion site.
- •Any condition that could interfere with participating in the trial, based on investigator judgment.
- •Participation in another pharmaceutical or device trial at the time of enrollment or during the study.
- •Having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the clinical trial
- •History of severe hypoglycemia in the past 6 months
- •History of DKA requiring hospitalization in the past 6 months
- •Significant chronic kidney disease (eGFR < 60) or hemodialysis
- •Significant liver disease
- •History of adrenal insufficiency
- •History of abnormal TSH consistent with hypothyroidism or hyperthyroidism that is not appropriately treated
- •History of high dose steroid use in the past 8 weeks
结局指标
主要结局
Time in Target Glucose Range
时间窗: Duration of iAPS Use During Pregnancy up to 40 weeks of Use
Time in target glucose range 63-140 mg/dL measured by CGM to determine safety and efficacy of the integrated system
次要结局
- Glucose > 180 mg/dL(Duration of iAPS Use During Pregnancy up to 40 weeks of Use)
- Glucose < 63 mg/dL(Duration of iAPS Use During Pregnancy up to 40 weeks of Use)
- Glucose > 140 mg/dL(Duration of iAPS Use During Pregnancy up to 40 weeks of Use)
- Glucose < 54 mg/dL(Duration of iAPS Use During Pregnancy up to 40 weeks of Use)
- Hypoglycemic Events Per Week(Duration of iAPS Use During Pregnancy up to 40 weeks of Use)
- Overnight Time in Target Glucose Range(Duration of iAPS Use During Pregnancy up to 40 weeks of Use)
- Hyperglycemic Events(Duration of iAPS Use During Pregnancy up to 40 weeks of Use)
- Serious Adverse Events (SAE)(Duration of iAPS Use During Pregnancy up to 40 weeks of Use)
- Adverse Device Effects (ADE)(Duration of iAPS Use During Pregnancy up to 40 weeks of Use)
- Postprandial Time in Target Glucose Range(Duration of iAPS Use During Pregnancy up to 40 weeks of Use)
- Severe Hypoglycemic Events(Duration of iAPS Use During Pregnancy up to 40 weeks of Use)
- Glucose > 250 mg/dL(Duration of iAPS Use During Pregnancy up to 40 weeks of Use)
- Serious Adverse Device Events (SADE)(Duration of iAPS Use During Pregnancy up to 40 weeks of Use)
- Unanticipated Adverse Device Effects (UADE)(Duration of iAPS Use During Pregnancy up to 40 weeks of Use)
- Mean CGM Glucose Level(Duration of iAPS Use During Pregnancy up to 40 weeks of Use)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
2 期
Safety and Feasibility Evaluation of the APS APPType 1 Diabetes MellitusNCT03504046Sansum Diabetes Research Institute6
招募中
不适用
A Study to Validate the Safety and Feasibility of ArtiSential in Colorectal Cancer Surgery Using Prospectively Constructed Multi-center RegistryRectal CancerRectosigmoid CancerRectosigmoid Junction CancerNCT05566249Samsung Medical Center1,000
终止
1 期
Processed Amniotic Fluid (pAF) for the Treatment of Chronic WoundsWounds and InjuriesNCT04438174University of Utah1
已完成
不适用
A Feasibility Study to Evaluate the Safety and Short-term Effectiveness of Transcatheter Pulmonary Valve (TPV)Congenital Heart DefectsCardiovascular AbnormalitiesPulmonary Valve InsufficiencyPulmonary Valve StenosisNCT02555319Seoul National University Hospital10
终止
不适用
Safety and Feasibility Evaluation of the Arterica Closure Device designed for the closure of artery access sites following Endovascular proceduresACTRN12620000773932Arterica, Inc.4